NCT03885947 2021-05-24
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
Clinical Trials
10 trialsNCT00414310 2019-05-21
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00075010 2018-11-15
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02144623 2017-03-03
PREVAIL
Lund University Hospital
Phase EARLY_PHASE1 Completed
NCT00867672 2016-08-31
DECIDER
University Hospital Freiburg
Phase 2 Completed
NCT00175812 2015-06-24
Differentiation Induction in Acute Myelogenous Leukemia
University of Bergen
Phase 1/2 Completed
NCT00995332 2015-06-24
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
University of Bergen
Phase 1/2 Completed
NCT00079378 2013-09-30
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00382590 2012-08-07
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00326170 2012-06-15
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
Phase 2 Completed